
|Articles|June 18, 2015
GSK's $95m Investment to Solve the Mysteries of Cell "Operating Codes"
June 18, 2015.
Advertisement
GSK is investing over $95m in new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions. The drug maker's investment will help launch the Altius Institute for Biomedical Sciences (Seattle, WA), which will be led by Dr John A. Stamatoyannopoulos, Professor of Genome Sciences and Medicine at the University of Washington School of Medicine.
GSK and Altius have signed a 10-year collaboration agreement that provides long-term support for innovative, high-impact research.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market
2
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion
3
Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last
4
Catalent Announces Expanded Partnership with Nanoscope Therapeutics
5




